Lincoln Pharma allocates approximately Rs 30 cr for expansion of cephalosporin product portfolio, Health News, ET HealthWorld
The factory will supply all cephalosporin products such as tablets, capsules, dry syrup and injectables. The company plans to start registering its products for the domestic and export markets soon, he added.
“The entire expansion of Cephalosporin products will be funded by internal provisions. The company has earmarked a total investment of approximately Rs 30 crore for this expansion,” said Lincoln Pharmaceuticals chief executive Mahendra Patel.
The company plans to manufacture more than 20 cephalosporin products, including cefalexin BP oral suspension, clavulanate tablets, cefixime capsules, cefuroxime axetil tablets, among others, according to the filing.
It plans to export the products to markets in Africa, Latin America and Southeast Asia, he added.
“Cephalosporin is a broad-spectrum bactericidal, P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infections, angina strep throat, staph infections, tonsillitis, bronchitis and the like, “the record says.
Lincoln Pharma shares were trading at Rs 386.80 per certificate on BSE, up 1.10% from its previous close.